BREAST CANCER METASTATIC

This early-stage study tests a new drug called SLV-154 in about 70 adults with advanced solid tumors that have spread. The main goal is to find the safest dose and check for side effects. Participants have cancers like head and neck, lung, breast, or ovarian cancer that haven't r…

This study tests a new drug called evorpacept combined with standard treatments (trastuzumab and chemotherapy) for people with advanced HER2-positive breast cancer that has worsened after prior therapy. About 120 participants will receive the combination to see if it shrinks tumo…

This early-stage study tests whether adding the drug avasopasem to standard hormone therapy and a CDK 4/6 inhibitor is safe and can help shrink or control metastatic hormone receptor positive breast cancer. About 35 women whose cancer has worsened on current treatments will parti…

This study tests the drug trastuzumab deruxtecan (T-DXd) in 40 adults with metastatic breast cancer that has no HER2 protein (HER2-IHC 0). The goal is to see if the drug can shrink tumors and which patients benefit most. Participants receive T-DXd and are monitored for response a…

This study tests a new treatment called Bria-IMT combined with an immunotherapy drug (retifanlimab) for people with advanced metastatic breast cancer who have run out of standard options. About 404 participants will be randomly assigned to receive either this new combination or a…

This early-stage trial is testing a new treatment for people with metastatic pancreatic or breast cancer that has spread. The treatment combines chemotherapy drugs with high-dose vitamin C and the patient's own stem cells to try to overcome drug resistance. The main goal is to ch…

This early-stage study tests a new drug called Sapu003 in people with advanced cancers that are sensitive to mTOR treatment, including certain breast cancers, kidney cancer, and liver cancer. The main goal is to find the safest dose and understand side effects. About 27 adults wi…

This study tests a new daily pill, INX-315, in 150 people with advanced breast, ovarian, or other solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink or control tumors. The study includes three parts: testing the…

This study tests different doses of the drug abemaciclib given together with radiation therapy for people with advanced hormone receptor-positive, HER2-negative breast cancer that has spread to the bone. The goal is to find the safest dose of abemaciclib when used alongside stand…

This study tests a new drug called OM-RCA-01 in people with several types of cancer that have spread and have a specific marker (FGFR1). The drug is an antibody given by IV every two weeks. The goal is to find a safe dose and see if it can slow tumor growth. About 58 adults with …

This early-stage trial tests a new treatment called ES2B-C001, given alone or with an adjuvant, for people with HER2-positive breast cancer that has spread and hasn't responded to at least two prior therapies. The main goal is to check safety and find the best dose. About 40 adul…

This study tests a special PET scan that uses a radioactive tracer to find low levels of HER2 protein in metastatic breast cancer. About 40 adults with HER2-low breast cancer will receive an injection of the tracer and be scanned 3-6 days later. The goal is to see if this scan ca…

This study is testing two new imaging agents that light up breast cancer cells on PET scans. Researchers want to see if these agents can find tumors and their spread more accurately than current methods. About 200 women with breast cancer or suspected breast cancer will receive t…

This study is testing whether a new type of PET scan (HER2-PET) can predict how well the drug T-DXd works in people with advanced breast cancer. About 100 participants with HER2-positive or HER2-low breast cancer will get the scan before starting T-DXd treatment. The goal is to s…

This study looks at different ways to find PIK3CA gene changes in people with metastatic breast cancer. The goal is to see which testing method works best so doctors can choose the right treatment for each patient. About 100 adults with hormone receptor-positive, HER2-negative br…

This study tests a special dye that makes cancer cells glow in lymph nodes removed during breast cancer surgery. The goal is to quickly tell if the cancer has spread, so surgeons can remove only the affected nodes and avoid extra surgery that can cause swelling and other problems…

This study aims to create and validate a blood test (liquid biopsy) that can detect two important gene mutations (ESR-1 and gBRCA) in patients with a common type of advanced breast cancer (HR+/HER2-). The test is designed to help doctors choose the most effective treatments. Rese…

This study looks at how willing and able women with non-metastatic breast cancer are to change their diet to reduce cancer risks. About 200 women who have finished primary treatment will complete online surveys and review an educational flyer. The goal is to understand what helps…

This study is collecting information from 200 patients in China with HER2-negative metastatic breast cancer who have received at least two cycles of the drug sacituzumab govitecan. Researchers want to see how well the drug works and how safe it is in everyday medical practice, no…

This study is testing a new blood test (called a liquid biopsy) to track breast cancer over time. About 93 women with early or advanced breast cancer will give blood samples at several visits. The goal is to see if counting cancer cells in the blood can give doctors useful inform…